Drug Profile


Alternative Names: Ad35HIV-EnvA; HIV adenovector serotype Ad35 vaccine - GenVec/NIAID; rAd35-EnvA vaccine; VRC-rAd35 HIV vaccine - GenVec

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GenVec; National Institute of Allergy and Infectious Diseases
  • Developer National Institute of Allergy and Infectious Diseases
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
  • 01 May 2014 GenVec and Vaccine Research Center complete a phase I clinical trial in HIV-1 infections (combination therapy, prevention, in volunteers) in USA (NCT00479999)
  • 04 Sep 2013 VRC-HIVADV027-00-VP is available for licensing as of 04 Sep 2013. http://www.genvec.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top